Viewing Study NCT06253494

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 1:40 AM

Ignite Modification Date: 2025-12-26 @ 5:40 AM

Study NCT ID: NCT06253494

Status: RECRUITING

Last Update Posted: 2025-12-01

First Post: 2024-02-09

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Sponsor: National Cancer Institute (NCI)

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module